ARAnoopraj Rajappan

Anoopraj Rajappan

*This is an algorithmically generated author record based on publicly available information.

Anoopraj Rajappan has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Bibu John Kariyil

    Department of Veterinary Pharmacology and Toxicology, College of Veterinary and Animal Sciences, Kerala Veterinary and Animal Sciences University, Mannuthy 680 651, Kerala, India

    1 shared publication
  • Nisha Aynikkattil Ravindran

    Professor and Head, Department of Veterinary Pharmacology and Toxicology, College of Veterinary and Animal Sciences University, Mannuthy -680651, Kerala, India

    1 shared publication
  • Pooja Krishna Kizhekku Veettil

    MVSc Scholar, Department of Veterinary Pharmacology and Toxicology, College of Veterinary and Animal Sciences University, Mannuthy -680651, Kerala, India

    1 shared publication
  • Preethy John

    Associate Professor, Department of Veterinary Pharmacology and Toxicology, College of Veterinary and Animal Sciences University, Mannuthy - 680651, Kerala, India

    1 shared publication
  • Reji Varghese

    Assistant Professor, Department of Veterinary Surgery and Radiology, College of Veterinary and Animal Sciences University, Mannuthy - 680651, Kerala, India

    1 shared publication
  • Suja Rani Sasidharan

    Professor, Department of Veterinary Pharmacology and Toxicology, College of Veterinary and Animal Sciences University, Mannuthy - 680651, Kerala, India

    1 shared publication

Latest Publications

  • Acute dermal toxicity evaluation of eugenol-incorporated hydrogel in Sprague Dawley rats

    by Pooja Krishna Kizhekku Veettil, Suja Rani Sasidharan, Nisha Ayinikkattil Ravindran, Preethy John, Anoopraj Rajappan, Reji Varghese

    Background: Multidrug-resistant Staphylococcus aureus (MDRSA) infections significantly impair wound healing, often leading to chronic wounds and systemic complications. There is a need for wound dressings that are not only antibacterial but also biocompatible. Essential oils, such as eugenol, possess potent antibacterial properties, but their direct application is limited by volatility and instability. Incorporating eugenol into a polymeric hydrogel provides a stable delivery system, while ensuring safety prior to in vivo use is essential. Objectives: This study aimed to evaluate the dermal safety of eugenol-incorporated chitosan-PVA hydrogel (Eug-CH) in Sprague Dawley rats, following OECD Test Guideline 402. Materials and Methods: The inert chitosan-PVA hydrogel was synthesised via chemical crosslinking, followed by incorporation of eugenol as an emulsion. Acute dermal toxicity testing was conducted according to OECD 402, with topical application to the dorsal skin under semi-occlusive conditions. Sequential doses up to 2000 mg/kg were administered, with a total of five female rats used. Animals were monitored intensively for 24 h post-application and daily for 14 days, assessing dermal integrity, behaviour and systemic signs of toxicity. Results: Topical application of Eug-CH produced no mortality or toxicity at doses up to the tested limit dose of 2000 mg/kg. Observations over 14 days revealed no adverse effects, including erythema, edema, tremors, convulsions, or behavioural abnormalities. Gross necropsy showed no organ abnormalities and a normal increase in body weight was noted. These findings indicate that the Eug-CH formulation is safe for dermal application in rats even upto the limit dose level. Conclusion: The Eug-CH hydrogel showed no mortality, skin irritation or pathological changes at doses ranging from 200 to 2000 mg/kg, with normal body weight gain observed over 14 days. With an LD₅₀ exceeding 2000 mg/kg, the formulation is classified as GHS Category 5 (low hazard), confirming its safety for regulatory purposes. These results indicate that the eugenol incorporated hydrogel is highly biocompatible and suitable as an antibacterial wound dressing without risk of dermal toxicity.

  • Open Access

    Ameliorative effects of eugenol and naringenin on perfluorooctanoic acid-induced hepatotoxicity in Sprague-Dawley rats

    by T Sherin, J K Bibu, R Anoopraj

    Perfluorooctanoic acid (PFOA), an environmental pollutant with wide industrial usage, is known to induce hepatotoxicity through oxidative stress, inflammation and lipid dysregulation. This study evaluated the hepatoprotective effects of eugenol and naringenin against PFOA–induced liver damage in Sprague-Dawley rats. Hepatotoxicity was induced via the oral administration of PFOA (40 mg/kg) for 21 days. Simultaneously, the rats were treated with eugenol (5 and 10 mg/kg) and naringenin (10 and 50 mg/kg). Serum biochemical parameters like alanine aminotransferase (ALT), aspartate aminotransferase (AST), cholesterol and triglycerides, liver thiobarbituric acid reactive substances (TBARS) levels and histopathological changes were assessed. In silico molecular docking was performed to explore the interactions of the test compounds with adiponectin. PFOA significantly elevated serum transaminases, lipid parameters and hepatic TBARS levels and induced histological changes such as steatosis, necrosis and inflammation. Treatment with eugenol and naringenin significantly (P < 0.05) mitigated these alterations, particularly at higher doses. Molecular docking revealed favourable binding affinities of both compounds with adiponectin, suggesting a mechanistic role in their hepatoprotective effects. Eugenol and naringenin exerted protective effects against PFOA-induced hepatotoxicity through antioxidant, anti–inflammatory and lipid–modulating actions, possibly via adiponectin signalling pathways. These findings highlight their therapeutic potential in managing environmentally induced liver damage.